Form 4: Emergent BioSolutions Executive Receives RSU Grant

Paul Anthony Williams, SVP of Products Business at Emergent BioSolutions, was granted 100,111 restricted stock units following shareholder approval of the company's incentive plan.

Summary

• Paul Anthony Williams, SVP of Products Business, acquired 100,111 restricted stock units (RSUs) of Emergent BioSolutions Inc. (EBS).
• The grant was originally approved by the Compensation Committee on March 2, 2026, contingent upon shareholder approval of the Amended 2006 Stock Incentive Plan.
• Shareholders approved the plan on April 29, 2026, triggering the formal issuance of the units.
• The RSUs vest in three equal annual installments, subject to continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of executive compensation with long-term shareholder interests through equity-based incentives.
• Successful shareholder approval of the Amended Stock Incentive Plan, providing the company with necessary tools for talent retention.

Negatives

• The issuance of 100,111 RSUs results in potential future dilution for existing shareholders.

Risks

• Vesting is contingent upon continued service, creating potential retention risk if the executive departs before the three-year period concludes.

Future Outlook

The RSUs will vest in three annual installments, incentivizing the executive to remain with the company through the vesting period.

Management Comments

• The grant is subject to the terms of the Amended Stock Incentive Plan and the specific grant agreement.

Industry Context

StockSavvy.ai notes that equity-based compensation remains a standard practice in the biotechnology sector to align executive performance with corporate milestones and shareholder value.

Comparison to Industry Standards

• The use of three-year vesting schedules for RSUs is consistent with standard corporate governance practices for executive compensation in the U.S. biotech industry.
• Granting equity contingent on shareholder approval of incentive plans is a standard regulatory requirement for publicly traded companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor dilution upon the eventual vesting and conversion of RSUs into common stock.

Next Steps

• Vesting of the first installment of RSUs on the anniversary of the approval date.

Key Dates

Keywords

Emergent BioSolutions, EBS, Form 4, Insider Trading, Executive Compensation, Restricted Stock Units, Stock Incentive Plan